Studies currently recruiting participants
RELMED
The RELMED study aims to improve depression treatment by finding which individual learning patterns and brain activity patterns could predict which antidepressant will work best for each individual. The study is not testing new drugs; it is testing a new way of selecting them. People who are depressed, but who have not been on anti-depressant medication within the last six weeks, may be eligible for this study. Participating involves being prescribed one of two anti-depressant medications, as well as completing online tasks and questionnaires, and optionally visiting the lab for an EEG reading of brain activity.
DRAIG Tarian-1
The goal of this trial is to learn if an investigational medicine, DT-101, can treat depression in adults. The study will evaluate the efficacy, safety, and tolerability of DT-101 in adults with major depressive disorder. Participants will be randomly assigned to take either DT-101 or a placebo (an inactive substance). Participants will attend the clinic every couple of weeks, complete general health checks and complete questionnaires.
Eligible participants will receive study-related care and evaluations at no cost. Compensation for your time and travel may be available.
ALTO-207-201
The purpose of this research study is to compare the effects of ALTO-207, the study’s investigational drug, versus placebo (an inactive substance) in treating symptoms of depression in participants who have Major Depressive Disorder (MDD) who are also taking a traditional anti-depressant medication.
RENEW-MDD-1
RENEW-MDD-1 is a clinical research study for adults with major depressive disorder (MDD) who are taking a treatment that is helping
manage their symptoms. Everyone who takes part will continue taking their current treatment. They will also take a placebo or investigational drug (the one being tested). The study will test if the investigational drug, as an addition to the current depression treatment, can prevent or minimise relapse and help people with MDD stay well for longer.
To join this study, you must:
- have MDD
- be taking a treatment for your depression
- currently your depressive symptoms are improved or well controlled
- You will continue taking your current depression treatment.
MD cohort study
The Mental Health Mission Mood Disorder Cohort Study is a study that is collecting data from a group of people (a “cohort”) who have depression that has been difficult to treat. This is an observational study (it does not involve any changes to someone’s treatment), and participants can take part in other interventional studies (studies that do involve changes in treatment) alongside the Cohort Study. Participants complete baseline psychological measures, and are invited to submit regular follow-up measures. The study aims to give researchers controlled access to research data from a large number of people so they can help develop more effective treatment approaches and ask questions such as why some people respond to treatments and others don’t. Baseline data held by the Cohort Study may mean it is easier to identify suitable candidates for other depression research studies, and Cohort Study participants can choose to be open to receiving invitations to participate in other studies. In this way, the Cohort Study also aims to give people with depression the best opportunity to take part in research.
Ongoing Studies (no longer recruiting)
Compass
Many people who receive antidepressant treatment for their depression do not get an adequate response to these treatments. This is sometimes referred to as treatment-resistant depression or TRD. This study will explore whether an investigational medicine, COMP360 together with psychological support is an effective treatment for people who have not been helped by prior treatment for their depression.
